Skip to content
TrackPodcasts
newsNov 14, 202336:51pending

Potential Shutdown and Drug Development

About this episode

Ira Jersey, Chief US interest rate strategist for Bloomberg Intelligence, discusses how Treasuries might react to a government shutdown on Friday. Michael Shah, Pharma Analyst with Bloomberg Intelligence, joins to discuss Novo Nordisk, Ozempic, and the weight loss drug push. Jake Saper, Emergence Capital General Partner, joins to talk about investment strategies, tech, and markets. Jereme Sylvain, CFO at DexCom (NASDAQ: DXCM), joins to discuss company earnings, its initiatives in healthcare and specifically for diabetes, and outlook for the firm and industry. Hosted by Paul Sweeney and Matt Miller.

See omnystudio.com/listener for privacy information.

Get every episode summarized

Each time Bloomberg Intelligence publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.

Email me new episodes

Free for 3 shows. No card needed.

No transcript yet

This episode has not been transcribed. Request it and it moves to the front of the queue.

Potential Shutdown and Drug Development

Bloomberg Intelligence

0:00
36:51

More episodes

More from Bloomberg Intelligence

View all episodes →